Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2012. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 1,500,000 Ordinary Shares on June 15, 2012.
- Price Range: Highest price paid was 1,459.0 pence; lowest price paid was 1,443.0 pence.
- Treasury Holdings (Settled): 462,607,927 shares (8.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 467,007,927 shares (9.33% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,003,055,346 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,500,000 shares for treasury purposes. This transaction increased the percentage of total voting rights held in treasury from the prior settled position to 9.33% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (462,607,927 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (9.33% held in treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (5,003,055,346 shares in issue).
- Review the price paid per share (1,443.0 to 1,459.0 pence) against market prices on June 15, 2012.